Synmosa Biopharma Corporation (TPEX:4114)
Taiwan · Delayed Price · Currency is TWD 31.75
-0.20 (-0.63%)
Apr 20, 2026, 1:00 PM CST
Synmosa Biopharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 821.85 | 684.68 | 594.83 | 799.09 | 303.86 |
Depreciation & Amortization | 335.64 | 335.41 | 334.83 | 315.64 | 297.29 |
Other Amortization | 7.56 | 6.56 | 5.09 | 4.74 | 4.77 |
Loss (Gain) From Sale of Assets | 0.66 | 0.44 | -0.12 | -281.43 | -11.86 |
Asset Writedown & Restructuring Costs | 12.07 | 0.24 | 10.86 | 15.22 | 8.21 |
Loss (Gain) From Sale of Investments | -64.74 | 63.83 | -49.82 | -50.41 | -4.75 |
Loss (Gain) on Equity Investments | 26.38 | 13.78 | 10.33 | 16.56 | 16.4 |
Stock-Based Compensation | 35.87 | 14.64 | 17.21 | 22.47 | 10.64 |
Provision & Write-off of Bad Debts | 0.61 | -0.49 | 6.74 | 3.41 | 1.82 |
Other Operating Activities | -234.34 | -188.89 | -98.04 | -59.33 | -147.25 |
Change in Accounts Receivable | -135.03 | -130.66 | -27.87 | -244.16 | -77.74 |
Change in Inventory | -486.49 | -110.39 | -305.39 | -120.94 | 16.87 |
Change in Accounts Payable | 89.49 | 47.31 | -8.09 | 147.95 | 65.26 |
Change in Unearned Revenue | -74.01 | -5.39 | 1.21 | 46.36 | -2.44 |
Change in Other Net Operating Assets | 76.04 | 49.55 | 20.15 | 15.08 | -26.21 |
Operating Cash Flow | 411.57 | 780.62 | 511.93 | 630.25 | 454.86 |
Operating Cash Flow Growth | -47.28% | 52.49% | -18.77% | 38.56% | 78.80% |
Capital Expenditures | -255.44 | -214.52 | -207.04 | -129.3 | -93.06 |
Sale of Property, Plant & Equipment | 0.14 | 3.13 | 1.62 | 305.18 | 240.57 |
Cash Acquisitions | - | - | -48.83 | -95.86 | -7.52 |
Sale (Purchase) of Intangibles | -25.7 | -55.13 | -53.48 | -55.03 | -49.07 |
Investment in Securities | -398.4 | -107.35 | -402.88 | -96.92 | -2.12 |
Other Investing Activities | 15.86 | 37.08 | -7.25 | 2.59 | -15.48 |
Investing Cash Flow | -663.54 | -336.8 | -717.87 | -69.33 | 73.33 |
Short-Term Debt Issued | 753.5 | 13.62 | 127.07 | - | 133 |
Long-Term Debt Issued | 189.81 | 159.01 | 493 | 350 | - |
Total Debt Issued | 943.31 | 172.62 | 620.07 | 350 | 133 |
Short-Term Debt Repaid | -741.93 | - | -50 | -179.76 | - |
Long-Term Debt Repaid | -247.74 | -72.09 | -1,532 | -344.65 | -381.84 |
Total Debt Repaid | -989.66 | -72.09 | -1,582 | -524.41 | -381.84 |
Net Debt Issued (Repaid) | -46.35 | 100.54 | -962.15 | -174.41 | -248.84 |
Issuance of Common Stock | 1,109 | - | 950 | 40.23 | 0.61 |
Repurchase of Common Stock | - | - | - | -108.97 | -51.64 |
Common Dividends Paid | -272.61 | -228.74 | -194.43 | -148.64 | -79.98 |
Other Financing Activities | 174.52 | -59.35 | 243.83 | 43.84 | 82.28 |
Financing Cash Flow | 964.2 | -187.55 | 37.24 | -347.95 | -297.57 |
Foreign Exchange Rate Adjustments | -7.1 | 11.27 | -0.39 | 6.52 | -0.81 |
Net Cash Flow | 705.14 | 267.55 | -169.09 | 219.48 | 229.82 |
Free Cash Flow | 156.14 | 566.1 | 304.89 | 500.95 | 361.81 |
Free Cash Flow Growth | -72.42% | 85.68% | -39.14% | 38.46% | 261.83% |
Free Cash Flow Margin | 2.52% | 10.20% | 5.93% | 11.42% | 11.18% |
Free Cash Flow Per Share | 0.32 | 1.22 | 0.68 | 1.16 | 0.83 |
Cash Interest Paid | 62.04 | 60.02 | 66.97 | 59.29 | 51.82 |
Cash Income Tax Paid | 232.56 | 198.33 | 172.08 | 69.76 | 65.01 |
Levered Free Cash Flow | -39.26 | 426.14 | 148.45 | 362.14 | 420.14 |
Unlevered Free Cash Flow | -0.48 | 462.45 | 190.44 | 399.33 | 452.62 |
Change in Working Capital | -530 | -149.57 | -319.99 | -155.72 | -24.26 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.